Credit Suisse (SIX:CSGN) analyst Matt Miksic reiterated a Buy rating on Alcon (NYSE:ALC) Inc on Monday, setting a price target of $63, which is approximately 2.39% above the present share price of $61.53.
Miksic expects Alcon Inc to post earnings per share (EPS) of -$0.12 for the third quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Alcon, with an average price target of $64.28.
The analysts price targets range from a high of $71.46 to a low of $55.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $1.84 billion and a net profit of -$28 million. The company's market cap is $30.04 billion.
According to TipRanks.com, Credit Suisse analyst Matt Miksic is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 10.1% and a 68.37% success rate.
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.